Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2008, 152(1):21-25 | DOI: 10.5507/bp.2008.003

TPL-2/COT AND COX-2 IN BREAST CANCER

Zuzana Krcovaa, Jiri Ehrmanna,c, Veronika Krejcia, Aris Eliopoulosb, Zdenek Kolara
a Laboratory of Molecular Pathology, Department of Pathology, Faculty of Medicine and Dentistry, Palacky University and University Hospital, 775 15 Olomouc, Czech Republic
b Molecular and Cellular Biology Laboratory, Basic Science Division, University of Crete Medical School, Heraklion, Crete, Greece
c Department of Histology and Embryology, Faculty of Medicine and Dentistry, Palacky University, 775 15 Olomouc, Czech Republic

Background: Breast cancer is the most common cancer in women worldwide and although mortality (129 000/year) stagnates, incidence (370 000/year) is increasing. In addition to histological type, grade, stage, hormonal and c-erbB2 status there is therefore a strong need for new and reliable prognostic and predictive factors.

Methods and results: This minireview focuses on two potential prognostic and predictive candidates Tpl2/Cot and COX-2 and summarise information about them.

Conclusion: Tumor progression locus 2 (Tpl2/Cot) is a serine/threonine protein kinase belonging to the family of MAP3 kinases. Activated Tpl2/Cot leads to induction of ERK1/2, JNK, NF-κB and p38MAPK pathways. The first study on Tpl2/Cot mRNA in breast cancer showed its increase in 40 % of cases of breast cancer but no available data exist on protein expression. Cyclo-oxygenase 2 (COX-2) is inducible by growth and inflammatory factors and contributes to the development of various tumours. Expression of COX-2 in breast cancer varied from 5-100 % in reviewed papers with significantly higher values in poorly differentiated tumours. Tpl2/Cot and COX-2 have their importance in different intracellular pathways and some of these are involved in cancer development. Briefly, the results from recent studies suggest that Tpl2/Cot and COX-2 could be prognostic factors in breast cancer.

Keywords: Tpl2, Cot, COX-2, Breast cancer

Received: February 10, 2008; Accepted: March 5, 2008; Published: June 1, 2008  Show citation

ACS AIP APA ASA Harvard Chicago IEEE ISO690 MLA NLM Turabian Vancouver
Krcova, Z., Ehrmann, J., Krejci, V., Eliopoulos, A., & Kolar, Z. (2008). TPL-2/COT AND COX-2 IN BREAST CANCER. Biomedical papers, 152(1), 21-25. doi: 10.5507/bp.2008.003
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Boyle P, Ferlay J. Cancer incidence and mortality in Europe, 2004. Ann Oncol. 2005; 16:481-8. Go to original source... Go to PubMed...
    2. Institute of Health Information and Statistics of the Czech Republic. Czech health statistics yearbook 2005. IHIS CR. Prague; 2006.
    3. Institute of Health Information and Statistics of the Czech Republic, National Oncologic Registry of the Czech Republic. Cancer incidence 2004 in the Czech Republic. IHIS CR, NOR CR. Prague; 2007.
    4. Tavassoli FA, Devilee P. World health organization classifi cation of tumors. Pathology and genetics of tumours of the breast and female genital organs. IARC Press: Lyon; 2003.
    5. Brenton JD, Carey LA, Ahmed AA, Caldas C. Molecular classifi cation and molecular forecasting of breast cancer: ready for clinical application? J Clin Oncol. 2005; 23:7350-60. Go to original source... Go to PubMed...
    6. Potti A, Dressman HK, Bild A, Riedel RF, Chan G, Sayer R et al. Genomic signatures to guide the use of chemotherapeutics. Nat Med. 2006; 12:1294-300. Go to original source... Go to PubMed...
    7. Jansen MP, Foekens JA, van Staveren IL, Dirkzwager-Kiel MM, Ritstier K, Look MP et al. Molecular classifi cation of tamoxifenresistant breast carcinomas by gene expression profi ling. J Clin Oncol. 2005; 23:732-40. Go to original source... Go to PubMed...
    8. Aggarwal BB, Shishodia S, Sandur SK, Pandey MK, Sethi G. Infl ammation and cancer: how hot is the link? Biochem Pharmacol. 2006; 72:1605-21. Go to original source... Go to PubMed...
    9. Larkins TL, Nowell M, Singh S, Sanford GL. Inhibition of cyclooxygenase- 2 decreases breast cancer cell motility, invasion and matrix metalloproteinase expression. BMC Cancer. 2006; 6:181. Available from: http://www.biomedcentral.com/1471-2407/6/181 Go to original source... Go to PubMed...
    10. Patriotis C, Makris A, Bear SE, Tsichlis PN. Tumor progression locus 2 (Tpl-2) encodes a protein kinase involved in the progression of rodent T-cell lymphomas and in T-cell activation. Proc Natl Acad Sci U S A. 1993; 90:2251-5. Go to original source... Go to PubMed...
    11. Lang V, Symons A, Watton SJ, Janzen J, Soneji Y, Beinke S et al. ABIN-2 forms a ternary complex with TPL-2 and NF-kappa B1 p105 and is essential for TPL-2 protein stability. Mol Cell Biol. 2004; 24:5235-48. Go to original source... Go to PubMed...
    12. Beinke S, Deka J, Lang V, Belich MP, Walker PA, Howell S et al. NF-kappaB1 p105 negatively regulates TPL-2 MEK kinase activity. Mol Cell Biol. 2003; 23:4739-52. Go to original source... Go to PubMed...
    13. Luciano BS, Hsu S, Channavajhala PL, Lin LL, Cuozzo JW. Phosphorylation of threonine 290 in the activation loop of Tpl2/ Cot is necessary but not suffi cient for kinase activity. J Biol Chem. 2004; 279:52117-23. Go to original source... Go to PubMed...
    14. Staff ord MJ, Morrice NA, Peggie MW, Cohen P. Interleukin-1 stimulated activation of the COT catalytic subunit through the phosphorylation of Thr290 and Ser62. FEBS Lett. 2006; 580:4010-4. Go to original source... Go to PubMed...
    15. Cho J, Tsichlis PN. Phosphorylation at Thr-290 regulates Tpl2 binding to NF-kappaB1/p105 and Tpl2 activation and degradation by lipopolysaccharide. Proc Natl Acad Sci U S A. 2005; 102:2350-5. Go to original source... Go to PubMed...
    16. Cho J, Melnick M, Solidakis GP, Tsichlis PN. Tpl2 (tumor progression locus 2) phosphorylation at Thr290 is induced by lipopolysaccharide via an Ikappa-B Kinase-beta-dependent pathway and is required for Tpl2 activation by external signals. J Biol Chem. 2005; 280:20442-8. Go to original source... Go to PubMed...
    17. Dumitru CD, Ceci JD, Tsatsanis C, Kontoyiannis D, Stamatakis K, Lin JH et al. TNF-alpha induction by LPS is regulated posttranscriptionally via a Tpl2/ERK- dependent pathway. Cell. 2000; 103:1071-83. Go to original source... Go to PubMed...
    18. Caivano M, Rodriguez C, Cohen P, Alemany S. 15-Deoxy- Delta12,14- prostaglandin J2 regulates endogenous Cot MAPK kinase kinase 1 activity induced by lipopolysaccharide. J Biol Chem. 2003; 278:52124-30. Go to original source... Go to PubMed...
    19. Banerjee A, Gugasyan R, McMahon M, Gerondakis S. Diverse Tolllike receptors utilize Tpl2 to activate extracellular signal-regulated kinase (ERK) in hemopoietic cells. Proc Natl Acad Sci U S A. 2006; 103:3274-9. Go to original source... Go to PubMed...
    20. Azambuja E, Durbecq V, Rosa D, Colozza M, Larsimont D, Piccart-Gebhart M et al.. HER-2 overexpression/amplifi cation and its interaction with taxane-based therapy in breast cancer. Ann Oncol. 2007. Available from: http://annonc.oxfordjournals.org/ cgi/content/full/mdm352v1 Go to original source...
    21. Kelly MG, Alvero AB, Chen R, Silasi DA, Abrahams VM, Chan S et al. TLR-4 signaling promotes tumor growth and paclitaxel chemoresistance in ovarian cancer. Cancer Res. 2006; 66:3859- 68. Go to original source... Go to PubMed...
    22. Das S, Cho J, Lambertz I, Kelliher MA, Eliopoulos AG, Du K et al. Tpl2/cot signals activate ERK, JNK, and NF-kappaB in a cell-type and stimulus-specifi c manner. J Biol Chem. 2005; 280:23748-57. Go to original source... Go to PubMed...
    23. Eliopoulos AG, Wang CC, Dumitru CD, Tsichlis PN. Tpl2 transduces CD40 and TNF signals that activate ERK and regulates IgE induction by CD40. EMBO J. 2003; 22:3855-64. Go to original source... Go to PubMed...
    24. Chan H, Reed JC. TRAF-dependent association of protein kinase Tpl2/COT1 (MAP3K8) with CD40. Biochem Biophys Res Commun. 2005; 328:198-205. Go to original source... Go to PubMed...
    25. Hill SC, Youde SJ, Man S, Teale GR, Baxendale AJ, Hislop A et al. Activation of CD40 in cervical carcinoma cells facilitates CTL responses and augments chemotherapy-induced apoptosis. J Immunol. 2005; 174:41-50. Go to original source... Go to PubMed...
    26. Tsatsanis Ch, Patriotis C, Bear SE, Tsichlis PN. The Tpl-2 protooncoprotein activates the nuclear factor of activated T cells and interleukin 2 expressions in T cell lines. Immunology. 1998; 95:3827-32. Go to original source... Go to PubMed...
    27. Sugimoto K, Ohata M, Miyoshi J, Ishizaki H, Tsuboi N, Masuda A et al. A serine/threonine kinase, Cot/Tpl2, modulates bacterial DNA-induced IL-12 production and Th cell diff erentiation. J Clin Invest. 2004; 114:857-66. Go to original source... Go to PubMed...
    28. Kikuchi T, Yoshikai Y, Miyoshi J, Katsuki M, Musikacharoen T, Mitani A et al. Cot/Tpl2 is essential for RANKL induction by lipid A in osteoblasts. J Dent Res. 2003; 82:546-50. Go to original source... Go to PubMed...
    29. Eliopoulos AG, Dumitru CD, Wang CC, Cho J, Tsichlis PN. Induction of COX-2 by LPS in macrophages is regulated by Tpl2- dependent CREB activation signals. EMBO J. 2002; 21:4831-40. Go to original source... Go to PubMed...
    30. Parameswaran N, Pao CS, Leonhard KS, Kang DS, Kratz M, Ley SC et al. Arrestin-2 and G protein-coupled receptor kinase 5 interact with NFkappaB1 p105 and negatively regulate lipopolysaccharide- stimulated ERK1/2 activation in macrophages. J Biol Chem. 2006; 281:34159-70. Go to original source... Go to PubMed...
    31. Hu Y, Green N, Gavrin LK, Janz K, Kaila N, Li HQ et al. Inhibition of Tpl2 kinase and TNFalpha production with quinoline-3-carbonitriles for the treatment of rheumatoid arthritis. Bioorg Med Chem Lett. 2006; 16:6067-72. Go to original source... Go to PubMed...
    32. Sourvinos G, Tsatsanis C, Spandidos DA. Overexpression of the Tpl-2/Cot oncogene in human breast cancer. Oncogene. 1999; 185:4968-73. Go to original source... Go to PubMed...
    33. Krcova Z, Ehrmann J, Eliopoulos A, Turashvili G, Klein J, Kolar Z et al. Tpl2/Cot as a new prognostic and predictive factor in breast cancer? Virchows Arch. 2007; 451:142-3.
    34. Gariboldi MB, Ravizza R, Molteni R, Osella D, Gabano E, Monti E. Inhibition of Stat3 increases doxorubicin sensitivity in a human metastatic breast cancer cell line. Cancer Lett. 2007; 258:181-8. Go to original source... Go to PubMed...
    35. Lin VC, Jin R, Tan PH, Aw SE, Woon CT, Bay BH. Progesterone induces cellular diff erentiation in MDA-MB-231 breast cancer cells transfected with progesterone receptor complementary DNA. Am J Pathol. 2003; 162:1781-7. Go to original source... Go to PubMed...
    36. Christoforidou AV, Papadaki HA, Margioris AN, Eliopoulos GD, Tsatsanis C. Expression of the Tpl2/Cot oncogene in human Tcell neoplasias. Mol Cancer. 2004 Dec 3;3(1): 34. Available from: http://www.molecular-cancer.com/content/3/1/34 Go to original source... Go to PubMed...
    37. Wendum D, Masliah J, Trugnan G, Flejou JF. Cyclooxygenase- 2 and its role in colorectal cancer development. Virchows Arch. 2004; 445:327-33. Go to original source... Go to PubMed...
    38. Howe LR, Subbaramaiah K, Brown AM, Dannenberg AJ. Cyclooxygenase-2: a target for the prevention and treatment of breast cancer. Endocr Relat Cancer. 2001; 8:97-114. Go to original source... Go to PubMed...
    39. Dannenberg AJ, Altorki NK, Boyle JO, Dang C, Howe LR, Weksler BB et al. Cyclo-oxygenase 2: a pharmacological target for the prevention of cancer. Lancet Oncol. 2001; 2:544-51. Go to original source... Go to PubMed...
    40. Howe LR, Dannenberg AJ. COX-2 inhibitors for the prevention of breast cancer. J Mammary Gland Biol Neoplasia. 2003; 8:31-43. Go to original source... Go to PubMed...
    41. Juuti A, Louhimo J, Nordling S, Ristimaki A, Haglund C. Cyclooxygenase-2 expression correlates with poor prognosis in pancreatic cancer. J Clin Pathol. 2006; 59:382-6. Go to original source... Go to PubMed...
    42. Panel V, Boelle PY, Ayala-Sanmartin J, Jouniaux AM, Hamelin R, Masliah J et al. Cytoplasmic phospholipase A2 expression in human colon adenocarcinoma is correlated with cyclooxygenase-2 expression and contributes to prostaglandin E2 production. Cancer Lett. 2006; 243:255-63. Go to original source... Go to PubMed...
    43. Perrone G, Santini D, Vincenzi B, Zagami M, La Cesa A, Bianchi A et al. COX-2 expression in DCIS: correlation with VEGF, HER- 2/neu, prognostic molecular markers and clinicopathological features. Histopathology. 2005; 46:561-8. Go to original source... Go to PubMed...
    44. Witton CJ, Hawe SJ, Cooke TG, Bartlett JM. Cyclooxygenase 2 (COX2) expression is associated with poor outcome in ER-negative, but not ER-positive, breast cancer. Histopathology. 2004; 45:47-54. Go to original source... Go to PubMed...
    45. Schmitz KJ, Wohlschlaeger J, Kimmig R, Otterbach F, Bohr J, Lee HS et al. Overexpression of cyclo-oxygenase-2 is an independent predictor of unfavourable outcome in node-negative breast cancer, but is not associated with protein kinase B (Akt) and mitogen-activated protein kinase (ERK1/2, p38) activation or with Her-2/neu signalling pathways. J Clin Pathol. 2006; 59:685-91. Go to original source... Go to PubMed...
    46. Cox DG, Buring J, Hankinson SE, Hunter DJ. A polymorphism in the 3' untranslated region of the gene encoding prostaglandin endoperoxide synthase 2 is not associated with an increase in breast cancer risk: a nested case-control study. Breast Cancer Res. 2007; 9(1):R3. Available from: http://breast-cancer-research.com/content/ 9/1/R3 Go to original source... Go to PubMed...
    47. Howe LR, Subbaramaiah K, Patel J, Masferrer JL, Deora A, Hudis C et al. Celecoxib, a selective cyclooxygenase 2 inhibitor, protects against human epidermal growth factor receptor 2 (HER-2)/neuinduced breast cancer. Cancer Res. 2002; 62:5405-7.
    48. Howe LR, Chang SH, Tolle KC, Dillon R, Young LJ, Cardiff RD et al. HER2/neuinduced mammary tumorigenesis and angiogenesis are reduced in cyclooxygenase-2 knockout mice. Cancer Res. 2005; 65:10113-9. Go to original source... Go to PubMed...

    Return to the content